Location Directory

Clinical trials in Birmingham, Alabama

This page shows live ClinicalTrials.gov search results for Birmingham, Alabama, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 7:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

9536

Shown on this page

Current sort

Institutions in Birmingham

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

University of Alabama at Birmingham

Live official records

Open in full search

Conditions: Obesity & Overweight, Gestational Diabetes Mellitus in Pregnancy, Gestational Weight Gain, Morbid Obesity, Nutrition Behavior
Interventions: Nutrition education; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: Female only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Endometrial Neoplasms
Interventions: Pembrolizumab, Carboplatin, Paclitaxel, Placebo for pembrolizumab, Docetaxel, Cisplatin, External Beam Radiotherapy (EBRT), Cisplatin (as radiosensitizer), Brachytherapy; Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 990 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 29
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more

Conditions: Sickle Cell Disease
Interventions: Etavopivat, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 49
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 37 more

Conditions: Obesity
Interventions: Maridebart Cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 3,853 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 74
States / cities: Anniston, Alabama • Daphne, Alabama • Mobile, Alabama + 59 more

Conditions: Osteopenia
Interventions: Time-restricted eating combined with resistance exercise (TRE+Ex), Habitual eating pattern combined with resistance exercise (HE+Ex); Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 50 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Autoimmune Disorders
Interventions: Ublituximab, Placebo for Ublituximab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 5 more

Conditions: Primary Biliary Cholangitis
Interventions: Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 31
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more

Conditions: Acute Myeloid Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone; Procedure · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 6 Months to 21 Years
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 186
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more

Conditions: Emphysema
Interventions: Zephyr Valve Procedure; Device
Lead sponsor: Pulmonx Corporation; Industry
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 11
States / cities: Birmingham, Alabama • Chicago, Illinois • Winfield, Illinois + 7 more

Conditions: HIV Infections
Interventions: Standard of Care (SOC) Oral ART, Oral RPV, Oral CAB, RPV-LA Loading Dose, CAB-LA Loading Dose, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 32
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more

Conditions: Liver Diseases, Liver Dysfunction, Liver Transplant Disorder, Liver Transplant Rejection
Interventions: LIVERguard; Device
Lead sponsor: Paragonix Technologies; Industry
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 15
States / cities: Birmingham, Alabama • San Diego, California • Stanford, California + 12 more

Conditions: Status Epilepticus
Interventions: Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg); Drug
Lead sponsor: University of Virginia; Other
Eligibility: 1 Year and older
Enrollment: 770 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 63
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 38 more

Clinical trials in Birmingham, Alabama

Filter and sort this location

Institutions in Birmingham

Live official records

Evaluation of Nutritional Interventions to Limit Gestational Weight Gain in Women With Class III Obesity (BMI >40)

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Time-Restricted Eating and Exercise for Bone Health

Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Zephyr Valve Registry (ZEVR)

The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

Global Utilization And Registry Database for Improved preservAtion of doNor Livers

Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)